{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:45:29Z","timestamp":1794901529550,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LTGY24H120002"],"award-info":[{"award-number":["LTGY24H120002"]}]},{"name":"Chen Jumei Foundation","award":["2025-KYY-518052-0055"],"award-info":[{"award-number":["2025-KYY-518052-0055"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-025-04212-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T04:24:40Z","timestamp":1751343880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-world outcomes of a loading phase with intravitreal faricimab in refractory Neovascular Age-Related Macular Degeneration (nAMD) patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Xu","family":"Yufeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ningxi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Mingzhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Weixin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Panpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"5 Suppl","key":"4212_CR1","first-page":"S112","volume":"26","author":"W Wong","year":"2020","unstructured":"Wong W. Managed care opportunities and approaches to select treatment for sight preservation. Am J Manag Care. 2020;26(5 Suppl):S112-7.","journal-title":"Am J Manag Care."},{"key":"4212_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-66014-7_1","volume":"1256","author":"TDL Keenan","year":"2021","unstructured":"Keenan TDL, Cukras CA, Chew EY. Age-Related Macular Degeneration: Epidemiology and Clinical Aspects. Adv Exp Med Biol. 2021;1256:1\u201331.","journal-title":"Adv Exp Med Biol."},{"issue":"1","key":"4212_CR3","doi-asserted-by":"publisher","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","volume":"13","author":"R Tamiya","year":"2023","unstructured":"Tamiya R, Hata M, Tanaka A, Tsuchikawa M, Ueda-Arakawa N, Tamura H, et al. Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep. 2023;13(1):21128.","journal-title":"Sci Rep."},{"key":"4212_CR4","doi-asserted-by":"crossref","unstructured":"Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A; International Retina Group. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Ophthalmology. 2018;125(2):267-275.","DOI":"10.1016\/j.ophtha.2017.08.031"},{"issue":"11","key":"4212_CR5","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1097\/IAE.0000000000002270","volume":"39","author":"M Iglicki","year":"2019","unstructured":"Iglicki M, Busch C, Loewenstein A, Fung AT, Invernizzi A, Mariussi M, et al. UNDERDIAGNOSED OPTIC DISK PIT MACULOPATHY: Spectral Domain Optical Coherence Tomography Features For Accurate Diagnosis. Retina. 2019;39(11):2161\u20136.","journal-title":"Retina."},{"issue":"8","key":"4212_CR6","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s40123-024-00980-5","volume":"13","author":"E Giancipoli","year":"2024","unstructured":"Giancipoli E, Guglielmi A, Bux AV, Clima GME, Pignatelli F, Boscia F, et al. Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME). Ophthalmol Ther. 2024;13(8):2163\u201384.","journal-title":"Ophthalmol Ther."},{"issue":"5","key":"4212_CR7","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/pharmaceutics15051413","volume":"15","author":"L Ferro Desideri","year":"2023","unstructured":"Ferro Desideri L, Traverso CE, Nicolo M, Munk MR. Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration. Pharmaceutics. 2023;15(5):1388.","journal-title":"Pharmaceutics."},{"key":"4212_CR8","doi-asserted-by":"crossref","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-98.","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"4212_CR9","doi-asserted-by":"crossref","unstructured":"Ashraf M, Souka AAR. Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. Eye (Lond).2017;31(11):1523-36.","DOI":"10.1038\/eye.2017.81"},{"key":"4212_CR10","doi-asserted-by":"crossref","unstructured":"Chamberlain M, Baird P, Dirani M, Guymer R. Unraveling a complex genetic disease: age-related macular degeneration. Surv Ophthalmol. 2006;51(6):576-86.","DOI":"10.1016\/j.survophthal.2006.08.003"},{"issue":"7","key":"4212_CR11","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1167\/iovs.08-1689","volume":"49","author":"PA Keane","year":"2008","unstructured":"Keane PA, Liakopoulos S, Ongchin SC, Heussen FM, Msutta S, Chang KT, Walsh AC, Sadda SR. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(7):3115\u201320.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"4212_CR12","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2147\/DDDT.S115121","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857\u201367.","journal-title":"Drug Des Devel Ther."},{"issue":"6","key":"4212_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1159\/000507711","volume":"243","author":"M Nicolo","year":"2020","unstructured":"Nicolo M, Morlacchi A, Cappelli F, Ferro Desideri L, Colombo V, Musetti D, et al. Real-Life Data in the Treatment of Neovascular Age-Related Macular Degeneration: Results from the Imaculaweb Registry Evaluated in a Single Italian Medical Retina Center. Ophthalmologica. 2020;243(6):453\u201360.","journal-title":"Ophthalmologica."},{"issue":"6","key":"4212_CR14","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1177\/1120672119880386","volume":"30","author":"M Battaglia Parodi","year":"2020","unstructured":"Battaglia Parodi M, Romano F, Arrigo A, Sacchi R, Scanzi G, Ferri C, et al. Real-life anti-vascular endothelial growth factor treatment for age-related macular degeneration and diabetic macular edema in an Italian tertiary referral hospital. Eur J Ophthalmol. 2020;30(6):1461\u20136.","journal-title":"Eur J Ophthalmol."},{"key":"4212_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu PS, Allingham MJ, Cousins SW. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82: 100906.","journal-title":"Prog Retin Eye Res."},{"issue":"5","key":"4212_CR16","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.survophthal.2022.04.003","volume":"67","author":"GS Sarohia","year":"2022","unstructured":"Sarohia GS, Nanji K, Khan M, Khalid MF, Rosenberg D, Deonarain DM, et al. Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes. Surv Ophthalmol. 2022;67(5):1346\u201363.","journal-title":"Surv Ophthalmol."},{"issue":"2","key":"4212_CR17","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40123-023-00647-7","volume":"12","author":"JG Garweg","year":"2023","unstructured":"Garweg JG, Blum CA, Copt RP, Eandi CM, Hatz K, Prunte CF, et al. Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects. Ophthalmol Ther. 2023;12(2):639\u201355.","journal-title":"Ophthalmol Ther."},{"issue":"5","key":"4212_CR18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/cells8050471","volume":"8","author":"RG Akwii","year":"2019","unstructured":"Akwii RG, Sajib MS, Zahra FT, Mikelis CM. Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology. Cells. 2019;8(5):400.","journal-title":"Cells."},{"issue":"10326","key":"4212_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet."},{"issue":"17","key":"4212_CR20","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study-6month results. Eye (Lond). 2023;37(17):3574\u201381.","journal-title":"Eye (Lond)."},{"issue":"15","key":"4212_CR21","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valent\u00edn-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: First report of real-world outcomes in an independent retina clinic. Eye (Lond). 2023;37(15):3282\u20139.","journal-title":"Eye (Lond)."},{"issue":"7","key":"4212_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/bjophthalmol-2018-312625","volume":"103","author":"JB Kumar","year":"2019","unstructured":"Kumar JB, Wai KM, Ehlers JP, Singh RP, Rachitskaya AV. Subfoveal choroidal thickness as a prognostic factor in exudative age-related macular degeneration. Br J Ophthalmol. 2019;103(7):918\u201321.","journal-title":"Br J Ophthalmol."},{"issue":"3","key":"4212_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","volume":"123","author":"H Koizumi","year":"2016","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, et al. Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: Twelve-month results. Ophthalmology. 2016;123(3):617\u201324.","journal-title":"Ophthalmology."},{"issue":"10","key":"4212_CR24","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1167\/iovs.09-3639","volume":"50","author":"DS McLeod","year":"2009","unstructured":"McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, Lutty GA, et al. Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50(10):4982\u201391.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"4","key":"4212_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/IAE.0000000000001689","volume":"38","author":"RF Spaide","year":"2018","unstructured":"Spaide RF. Disease expression in nonexudative age-related macular degeneration varies with choroidal thickness. Retina. 2018;38(4):708\u201316.","journal-title":"Retina."},{"issue":"1","key":"4212_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","volume":"8","author":"A Szigiato","year":"2024","unstructured":"Szigiato A, Mohan N, Talcott KE, Mammo DA, Babiuch AS, Kaiser PK, et al. Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy. Ophthalmol Retina. 2024;8(1):10\u20137.","journal-title":"Ophthalmol Retina."},{"issue":"1","key":"4212_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12886-024-03663-8","volume":"24","author":"R Mukai","year":"2024","unstructured":"Mukai R, Honjo J, Tanaka K, Sekiryu T. Exploring the comparative regressive effects of aflibercept and faricimab on pigment epithelial detachment. BMC Ophthalmol. 2024;24(1):393.","journal-title":"BMC Ophthalmol."},{"issue":"4","key":"4212_CR28","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ajo.2015.06.025","volume":"160","author":"A Dirani","year":"2015","unstructured":"Dirani A, Ambresin A, Marchionno L, Decugis D, Mantel I. Factors influencing the treatment response of pigment epithelium detachment in age-related macular degeneration. Am J Ophthalmol. 2015;160(4):732-8.e2.","journal-title":"Am J Ophthalmol."},{"issue":"4","key":"4212_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/IAE.0000000000003283","volume":"42","author":"V Chaudhary","year":"2022","unstructured":"Chaudhary V, Matonti F, Zarranz-Ventura J, Stewart MW. Impact of fluid compartments on functional outcomes for patients with neovascular age-related macular degeneration: a systematic literature review. Retina. 2022;42(4):589\u2013606.","journal-title":"Retina."},{"issue":"9","key":"4212_CR30","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","volume":"122","author":"AS Willoughby","year":"2015","unstructured":"Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, et al. Subretinal hyper-reflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(9):1846-53.e5.","journal-title":"Ophthalmology."},{"issue":"1","key":"4212_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/vision2010005","volume":"2","author":"KFC Leung","year":"2018","unstructured":"Leung KFC, Downes SM, Chong V. A retrospective analysis of the effect of subretinal hyper-reflective material and other morphological features of neovascular age-related macular degeneration on visual acuity outcomes in eyes treated with intravitreal aflibercept over one year. Vision. 2018;2(1):5.","journal-title":"Vision."},{"issue":"6","key":"4212_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/iovs.63.6.17","volume":"63","author":"JP Ehlers","year":"2022","unstructured":"Ehlers JP, Patel N, Kaiser PK, Heier JS, Brown DM, Meng X, et al. The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD. Invest Ophthalmol Vis Sci. 2022;63(6):17.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"11","key":"4212_CR33","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s00417-020-04869-4","volume":"258","author":"M Woronkowicz","year":"2020","unstructured":"Woronkowicz M, Lightman S, Tomkins-Netzer O. The prognostic value of total macular external limiting membrane and ellipsoid zone damage for clinical outcome in treatment-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2020;258(11):2373\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"issue":"2","key":"4212_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00417-012-2034-4","volume":"251","author":"A Oishi","year":"2013","unstructured":"Oishi A, Shimozono M, Mandai M, Hata M, Nishida A, Kurimoto Y. Recovery of photoreceptor outer segments after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251(2):435\u201340.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"issue":"4","key":"4212_CR35","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ajo.2012.11.003","volume":"155","author":"R Mathew","year":"2013","unstructured":"Mathew R, Richardson M, Sivaprasad S. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab. Am J Ophthalmol. 2013;155(4):720-6.e1.","journal-title":"Am J Ophthalmol."},{"issue":"3","key":"4212_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ophtha.2011.09.027","volume":"119","author":"AR Rudnicka","year":"2012","unstructured":"Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology. 2012;119(3):571\u201380.","journal-title":"Ophthalmology."},{"issue":"16","key":"4212_CR37","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.3390\/ijms23169424","volume":"23","author":"S Liberski","year":"2022","unstructured":"Liberski S, Wichrowska M, Koci\u0119cki J. Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review. Int J Mol Sci. 2022;23(16):9424.","journal-title":"Int J Mol Sci."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04212-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04212-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04212-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T04:24:41Z","timestamp":1751343881000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04212-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4212"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04212-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Review Board of Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou 310009, People's Republic of China (2024-0621). All patients provided informed consent in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"347"}}